Other Species / Isoforms
  USP16 (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

  HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
K9-ub
GKKRTKGktVPIDDS
0 2
USP16 (human) GKKRTKGktVPIDDS K9-ub
USP16 (mouse) GKKRTKGRSAPDTVA R9
USP16 (rat) GKKRTKGKSVPEKAS K9
T10-p
KKRTKGktVPIDDSS
0 1
USP16 (human) KKRTKGktVPIDDSS T10-p
USP16 (mouse) KKRTKGRSAPDTVAs S10
USP16 (rat) KKRTKGKSVPEKASS S10
S17
tVPIDDSSETLEPVC
0 2
USP16 (human) tVPIDDSSETLEPVC S17
USP16 (mouse) SAPDTVAsESAEPVC S17-p
USP16 (rat) SVPEKASSESTEPMC S17
K29-ac
PVCRHIRkGLEQGNL
0 2
USP16 (human) PVCRHIRkGLEQGNL K29-ac
USP16 (mouse) PVCRHLRKGLEQGNL K29
USP16 (rat) PMCRHLRKGLEQGNL K29
K29-ub
PVCRHIRkGLEQGNL
0 1
USP16 (human) PVCRHIRkGLEQGNL K29-ub
USP16 (mouse) PVCRHLRKGLEQGNL K29
USP16 (rat) PMCRHLRKGLEQGNL K29
K37-ac
GLEQGNLkKALVNVE
0 2
USP16 (human) GLEQGNLkKALVNVE K37-ac
USP16 (mouse) GLEQGNLKKALVNVE K37
USP16 (rat) GLEQGNLKKALVNVE K37
K37-ub
GLEQGNLkKALVNVE
0 2
USP16 (human) GLEQGNLkKALVNVE K37-ub
USP16 (mouse) GLEQGNLKKALVNVE K37
USP16 (rat) GLEQGNLKKALVNVE K37
S189-p
KENPPMNsPCQITVK
0 4
USP16 (human) KENPPMNsPCQITVK S189-p
USP16 (mouse) KETIPMDSASQITVK S188
USP16 (rat) KENIPLDSASQITVK S188
S199-p
QITVKGLsNLGNTCF
0 1
USP16 (human) QITVKGLsNLGNTCF S199-p
USP16 (mouse) QITVKGLSNLGNTCF S198
USP16 (rat) QITVKGLSNLGNTCF S198
S230-p
LLKEVKMsGTIVKIE
0 1
USP16 (human) LLKEVKMsGTIVKIE S230-p
USP16 (mouse) LLKEVKMSGTIVKIE S229
USP16 (rat) LLKEVKMSGTIVKIE S229
K279
KKGVVTPKELFSQVC
0 1
USP16 (human) KKGVVTPKELFSQVC K279
USP16 (mouse) KKRVVTPkELFSQVC K278-ub
USP16 (rat) KKRIVTPKELFSQVC K278
K293-ub
CKKAVRFkGYQQQDS
0 7
USP16 (human) CKKAVRFkGYQQQDS K293-ub
USP16 (mouse) CKKATRFkGYQQQDS K292-ub
USP16 (rat) CKKATRFKGYQQQDS K292
S330-p
ILKAFGNsTEkLDEE
Upstream
Downstream
1 2
Effects on Modified Protein
  • enzymatic activity, induced
Kinase, in vitro:
  • PLK1 (human)
Putative in vivo kinases:
  • PLK1 (human)
USP16 (human) ILKAFGNsTEkLDEE S330-p
USP16 (mouse) ILKAFGNSTEKLDEE S329
USP16 (rat) ILKAFGNSTEKLDEE S329
K333-ub
AFGNsTEkLDEELKN
0 1
USP16 (human) AFGNsTEkLDEELKN K333-ub
USP16 (mouse) AFGNSTEKLDEEVKN K332
USP16 (rat) AFGNSTEKLDEEVKN K332
S353-p
EKKKSMPsFVDRIFG
0 1
USP16 (human) EKKKSMPsFVDRIFG S353-p
USP16 (mouse) EKKKAIPSFVDRIFG S352
USP16 (rat) EKKKAIPSFVDRIFG S352
S386-p
HESFLDLsLPVLDDQ
Upstream
Downstream
1 1
Effects on Modified Protein
  • enzymatic activity, induced
Kinase, in vitro:
  • PLK1 (human)
Putative in vivo kinases:
  • PLK1 (human)
USP16 (human) HESFLDLsLPVLDDQ S386-p
USP16 (mouse) HESFLDLSLPVLDDQ S385
USP16 (rat) HESFLDLSLPVLDDQ S385
S415-p
VEDEDQDsEEEKDND
Upstream
Downstream
1 39
Effects on Modified Protein
  • protein degradation
Putative in vivo kinases:
  • TTK (human)
Treatment
  • BI2536
USP16 (human) VEDEDQDsEEEKDND S415-p
USP16 (mouse) MEEEDKDsEEEKDDS S414-p
USP16 (rat) MEEEDKDsEEEKDDS S414-p
S423-p
EEEKDNDsYIkERSD
0 1
USP16 (human) EEEKDNDsYIkERSD S423-p
USP16 (mouse) sEEEKDDSYMKSRSD S421
USP16 (rat) sEEEKDDSYMKTRSD S421
K426-ub
KDNDsYIkERSDIPS
0 2
USP16 (human) KDNDsYIkERSDIPS K426-ub
USP16 (mouse) EKDDSYMKSRSDLPS K424
USP16 (rat) EKDDSYMKTRSDVPS K424
K437-ub
DIPSGTSkHLQKKAK
0 3
USP16 (human) DIPSGTSkHLQKKAK K437-ub
USP16 (mouse) DLPSGTSKHLQKKAK K435
USP16 (rat) DVPSGTSKHTQKKAK K435
S486-p
SEYEAEMsLQGEVNI
Upstream
Downstream
1 1
Effects on Modified Protein
  • enzymatic activity, induced
Kinase, in vitro:
  • PLK1 (human)
USP16 (human) SEYEAEMsLQGEVNI S486-p
USP16 (mouse) NEREADTALAGEVEV A484
USP16 (rat) NDHEAETALPGEGEV A484
K506-ub
SQEGVMHkEyCVNQk
0 2
USP16 (human) SQEGVMHkEyCVNQk K506-ub
USP16 (mouse) SQEEATQIELSVNQK I506
USP16 (rat) SQEELTQTELCANQK T506
Y508-p
EGVMHkEyCVNQkDL
0 1
USP16 (human) EGVMHkEyCVNQkDL Y508-p
USP16 (mouse) EEATQIELSVNQKDL L508
USP16 (rat) EELTQTELCANQKDV L508
K513-ub
kEyCVNQkDLNGQAk
0 1
USP16 (human) kEyCVNQkDLNGQAk K513-ub
USP16 (mouse) IELSVNQKDLDGQEs K513
USP16 (rat) TELCANQKDVNGQEE K513
K520
kDLNGQAKMIEsVTD
0 1
USP16 (human) kDLNGQAKMIEsVTD K520
USP16 (mouse) KDLDGQEsMIERTPD S520-p
USP16 (rat) KDVNGQEEMIESAAD E520
K520-ub
kDLNGQAkMIEsVTD
0 1
USP16 (human) kDLNGQAkMIEsVTD K520-ub
USP16 (mouse) KDLDGQESMIERTPD S520
USP16 (rat) KDVNGQEEMIESAAD E520
S524-p
GQAkMIEsVTDNQKs
0 1
USP16 (human) GQAkMIEsVTDNQKs S524-p
USP16 (mouse) GQEsMIERTPDVQEs R524
USP16 (rat) GQEEMIESAADERKC S524
S531-p
sVTDNQKsTEEVDMK
0 5
USP16 (human) sVTDNQKsTEEVDMK S531-p
USP16 (mouse) RTPDVQEsPEDLGVK S531-p
USP16 (rat) SAADERKCPEHPEVK C531
T550-p
DNDLEVLtssPtRNL
0 1
USP16 (human) DNDLEVLtssPtRNL T550-p
USP16 (mouse) ESDLGIVTPAPECPR T550
USP16 (rat) ESDLGSLTSAPECPR T550
S551-p
NDLEVLtssPtRNLN
0 3
USP16 (human) NDLEVLtssPtRNLN S551-p
USP16 (mouse) SDLGIVTPAPECPRD P551
USP16 (rat) SDLGSLTSAPECPRD S551
S552-p
DLEVLtssPtRNLNG
Upstream
Downstream
3 23
Effects on Modified Protein
  • intracellular localization
  • molecular association, regulation
  • protein degradation
Effects on Biological Processes:
  • cell cycle regulation
Kinase, in vitro:
  • CDK1 (human)
Putative in vivo kinases:
  • CDK1 (human)
  • TTK (human)
Treatment
  • antibody
  • CGP74514A
  • seliciclib
view more >
USP16 (human) DLEVLtssPtRNLNG S552-p
USP16 (mouse) DLGIVTPAPECPRDF A552
USP16 (rat) DLGSLTSAPECPRDL A552
T554-p
EVLtssPtRNLNGAY
Upstream
Downstream
1 5
Effects on Modified Protein
  • protein degradation
Putative in vivo kinases:
  • TTK (human)
USP16 (human) EVLtssPtRNLNGAY T554-p
USP16 (mouse) GIVTPAPECPRDFNG E554
USP16 (rat) GSLTSAPECPRDLNG E554
N567
AYLTEGSNGEVDISN
0 1
USP16 (human) AYLTEGSNGEVDISN N567
USP16 (mouse) AFLEERTsGELDIIN S569-p
USP16 (rat) AFLEERTSGELDITN S569
S598-p
NIEILNDsHtPGTKV
0 1
USP16 (human) NIEILNDsHtPGTKV S598-p
USP16 (mouse) NIEIPNDSHSAPKVY S600
USP16 (rat) SIEILNDSHSPALKV S600
T600-p
EILNDsHtPGTKVyE
0 1
USP16 (human) EILNDsHtPGTKVyE T600-p
USP16 (mouse) EIPNDSHSAPKVYEV S602
USP16 (rat) EILNDSHSPALKVYE S602
Y606-p
HtPGTKVyEVVNEDP
0 1
USP16 (human) HtPGTKVyEVVNEDP Y606-p
USP16 (mouse) SHSAPKVYEVMNEDP Y607
USP16 (rat) HSPALKVYEVMNEDP Y608
K682
HVYTNAKKQMLISLA
0 1
USP16 (human) HVYTNAKKQMLISLA K682
USP16 (mouse) HVYTNAKkQMLVSLA K683-ac
USP16 (rat) HVYTNAKKQMLVSLA K684
Y742-p
EENTRVLysLYGVVE
Upstream
0 2
Treatment
  • ischemia
USP16 (human) EENTRVLysLYGVVE Y742-p
USP16 (mouse) EESTRVLysLYGVVE Y743-p
USP16 (rat) EESTRVLYSLYGVVE Y744
S743-p
ENTRVLysLYGVVEH
Upstream
0 2
Treatment
  • ischemia
USP16 (human) ENTRVLysLYGVVEH S743-p
USP16 (mouse) ESTRVLysLYGVVEH S744-p
USP16 (rat) ESTRVLYSLYGVVEH S745
K764-ub
GHYTAYAkARTANSH
0 2
USP16 (human) GHYTAYAkARTANSH K764-ub
USP16 (mouse) GHYTAYAKERTASCH K765
USP16 (rat) GHYTAYAKERTASCH K766